Literature DB >> 15579639

Enforced activation of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem cells that contribute to hematopoiesis in vivo.

Jan Jacob Schuringa1, Kaida Wu, Giovanni Morrone, Malcolm A S Moore.   

Abstract

Little is known about the molecular mechanisms that direct the transition from primitive to definitive hematopoiesis. In this study, we cocultured murine embryonic stem (ES) cells on OP9 stroma to induce hematopoietic differentiation as a model to study factors involved in the generation of adult hematopoietic stem cells (HSCs). Overexpression of the constitutively activated mutant signal transducer and activator of transcription (STAT) 5A(1*6) in ES cells facilitated the generation of cells that expressed the endothelial-hemangioblast marker Flk-1 within 5 days of coculture on OP9. The first CD41+/ CD45+/c-Kit+/(Flk-1)- hematopoietic cells arose in our culture conditions between days 5 and 7. Persistent activation of STAT5A greatly enhanced the generation of hematopoietic progenitors compared with controls, as determined by colony assays in methylcellulose. Moreover, whereas controls generated only a short transient wave of hematopoiesis lasting less than 3 weeks, expression of STAT5A(1*6) resulted in the generation of hematopoietic cobblestone area-forming cells (CAFCs) on OP9 that could be serially passaged onto new OP9, giving rise to second and third CAFCs that generated hematopoietic progenitors for > or = 5 weeks, indicating a role for STAT5A in HSC self-renewal in vitro. Several definitive hematopoietic genes were upregulated by STAT5A (1*6), as well as Runx1/AML1, vascular endothelial growth factor, oncostatin M receptor, HoxB4, Wnt5A, Delta-like-1, and Bmi-1. Furthermore, ES-derived hematopoietic cells expressing STAT5A(1*6) contributed to myeloid-lymphoid hematopoiesis in primary and secondary nonobese diabetic-severe combined immunodeficiency recipients, although no donor-derived cells could be detected after 7 weeks in the secondary recipients. These data indicate that a persistent activation of STAT5A allows the generation of ES-derived HSCs that can, at least for an intermediate period, contribute to hematopoiesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579639     DOI: 10.1634/stemcells.2004-0033

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  22 in total

1.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B.

Authors:  Akiko Kimura; Cyril Martin; Gertraud W Robinson; James M Simone; Weiping Chen; Mark C Wickre; John J O'Shea; Lothar Hennighausen
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 3.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

4.  ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling.

Authors:  Andrew D Wood; Edwin Chen; Ian J Donaldson; Shilpa Hattangadi; Karly A Burke; Mark A Dawson; Diego Miranda-Saavedra; Harvey F Lodish; Anthony R Green; Berthold Göttgens
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

5.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Authors:  Sara C Meyer; Matthew D Keller; Sophia Chiu; Priya Koppikar; Olga A Guryanova; Franck Rapaport; Ke Xu; Katia Manova; Dmitry Pankov; Richard J O'Reilly; Maria Kleppe; Anna Sophia McKenney; Alan H Shih; Kaitlyn Shank; Jihae Ahn; Eftymia Papalexi; Barbara Spitzer; Nick Socci; Agnes Viale; Emeline Mandon; Nicolas Ebel; Rita Andraos; Joëlle Rubert; Ernesta Dammassa; Vincent Romanet; Arno Dölemeyer; Michael Zender; Melanie Heinlein; Raajit Rampal; Rona Singer Weinberg; Ronald Hoffman; William R Sellers; Francesco Hofmann; Masato Murakami; Fabienne Baffert; Christoph Gaul; Thomas Radimerski; Ross L Levine
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

Review 6.  Designer blood: creating hematopoietic lineages from embryonic stem cells.

Authors:  Abby L Olsen; David L Stachura; Mitchell J Weiss
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

7.  MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Authors:  Takashi Yokoyama; Mayuka Nakatake; Takeshi Kuwata; Arnaud Couzinet; Ryo Goitsuka; Shuichi Tsutsumi; Hiroyuki Aburatani; Peter J M Valk; Ruud Delwel; Takuro Nakamura
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

8.  Combined analysis of circRNA and mRNA profiles and interactions in patients with Diabetic Foot and Diabetes Mellitus.

Authors:  Wanni Zhao; Jianfeng Liang; Zuoguan Chen; Yongpeng Diao; Gang Miao
Journal:  Int Wound J       Date:  2020-06-23       Impact factor: 3.315

9.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

10.  GPR126 protein regulates developmental and pathological angiogenesis through modulation of VEGFR2 receptor signaling.

Authors:  Hengxiang Cui; Yeqi Wang; Huizhe Huang; Wenjie Yu; Min Bai; Long Zhang; Brad A Bryan; Yuan Wang; Jian Luo; Dali Li; Yanlin Ma; Mingyao Liu
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.